Aug 13, 2020
Akcea Announces New Pricing and Reimbursement of WAYLIVRA® (volanesorsen) in Germany
Jun 17, 2020
Akcea Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
Jun 05, 2020
Ionis Pharmaceuticals to present at upcoming virtual investor conferences
May 07, 2020
Duchenne Muscular Dystrophy Market is Anticipated to Grow With a CAGR of 31.8% for the Study Period of 2017-2030: DelveInsight
Apr 20, 2020
Ionis and partner announce enrollment completion of global Phase 3 GENERATION HD1 study for Huntington's disease
Feb 27, 2020
Ionis Pharmaceuticals to present at upcoming investor conferences
Jan 22, 2020
Akcea and Ionis report positive topline Phase 2 results of AKCEA-APOCIII-L Rx
Jan 08, 2020
n-Lorem Foundation established to charitably provide antisense medicines to treat patients with ultra-rare diseases
Jan 07, 2020
Ionis' neurological franchise marks year of achievement
Oct 28, 2019
Bench to bedside strategies demonstrate Ionis' foremost expertise in RNA-targeted therapeutics at DIA/FDA Oligonucleotide Conference
Sep 24, 2019
Obsidian Therapeutics Appoints Erin Boyer as Vice President, Human Resources
Sep 17, 2019
Positive preliminary results from ATL1102 for DMD Phase II trial
Jul 23, 2019
Alnylam Launches ONPATTRO® (patisiran) for the Treatment of Polyneuropathy in hATTR Amyloidosis, the First-Ever RNAi Therapeutic Approved in Canada
Jun 18, 2019
Ionis Pharmaceuticals to present at the BMO Prescription for Success Healthcare Conference
Apr 08, 2019
Regeneron and Alnylam Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases
Mar 25, 2019
Ionis announces appointment of Brett P. Monia Ph.D. to its board of directors
Mar 07, 2019
Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
Jan 04, 2019
MabVax Therapeutics and Oncotelic Enter into Merger Discussions
Jan 02, 2019
Ionis Pharmaceuticals to Present at 37th Annual J.P. Morgan Healthcare Conference
Nov 27, 2018
First-in-class therapies using advanced antisense chemistries highlighted at 2018 American Society of Hematology Annual Meeting